METHOD OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

The present invention relates to a novel method for the treatment of motor neurone diseases and in particular of amyotrophic lateral sclerosis (ALS). It equally relates to vectors and pharmaceutical compositions allowing the prolonged expression of therapeutic factors, utilizable for the treatment of ALS. More precisely, the present invention relates to the treatment of ALS by systemic administration of therapeutic genes.

Amyotrophic lateral sclerosis (ALS), also known under the name of Charcot's disease and Lou Gehrig's disease was described for the first time by Charcot in 1865. ALS is a fatal disease resulting from the degeneration of motor neurones and corticospinal tracts. With an incidence at present of 2.5/100,000 and, constantly on the increase, a prevalence of 6 - 10/100,000, ALS affects 90,000 people in the developed countries, for the most part adults who are still relatively young (between 50 and 60). The disease is accompanied by progressive paralysis, leading to the total loss of motor and respiratory functions and then to death with a delay of two to eight years after the appearance of the first symptoms (three years on average).

5% of the cases of ALS are of familial origin and 95% of the cases are sporadic. The physio-pathological origin of the sporadic forms of ALS remains unknown. Several hypotheses have been proposed. The motor neurone

degeneration could result from an alteration in the
metabolism of glutamate leading to an increase in the
concentration of this exciter amino acid in the motor cortex
and the spinal cord ("excitotoxic" hypothesis, review in
5   Rothstein, 1995). The possibility of an autoimmune component
has likewise been put forward on the basis of the presence
of auto-antibody against the voltage-sensitive calcium
channels in certain patients (review in Appel et al., 1995).
The implication of environmental factors such as exposure to
10 certain viruses (review in Gastaut, 1995), or to aluminium
(Yase, 1984) is likewise possible.

The studies bearing on the hereditary forms of ALS have
allowed it to be shown that point mutations in the gene for
cupro-zinc containing superoxide dismutase, localized on the
15 21q22-1 chromosome, are responsible for the pathology in 20%
of the familial forms (Rosen et al., 1993, review in
Rowland, 1995). These mutations do not cause reduction of
the dismutase activity of the SOD (review in Rowland, 1995).
The mutated enzymes produce potentially cytotoxic hydroxyl
20 radicals which are not produced by the wild-type SOD (Yim et
al., 1996). The detailed study of the functional effect of
the mutations on the enzymatic activity of the SOD and on
the cellular viability in the end ought to allow the
physiopathology of the familial forms of ALS to be
25 understood, and, by extension, light to be thrown on the
physiopathology of all of the forms of ALS.

Work bearing on factors capable of influencing the

survival of the motor neurones has allowed a potential neuroprotector role of several neurotrophic factors to be demonstrated (review in Windebank, 1995; Henderson, 1995). Thus, motor neurone protection effects *in vitro* have been observed especially with BDNF (Oppenheim et al., 1992, Yan et al., 1992 Sendtner et al., 1992, Henderson et al., 1993, Vejsada et al., 1995), GDNF (Henderson et al., 1994, Oppenheim et al., 1995), three cytokines, CNTF, LIF (review in Henderson, 1995) and cardiotrophin-1 (Pennica et al., 1996), with IGF-1 (Lewis et al., 1993) and members of the FGF family (Hughes et al., 1993). All of these data suggest that the neurotrophic factors mentioned increase the survival of motor neurones under various experimental conditions. However, the use of neurotrophic factors in animal models of ALS or in human clinical trials as yet have not given convincing results. This use has never demonstrated any therapeutic effect and is always accompanied by undesirable secondary effects such as loss of weight, inflammation, fever, etc., which limit interest in trophic factors in the treatment of ALS and have led to the premature interruption of the first ALS-CNTF clinical trials by Regeneron (systemic administration) (Barinaga et al., 1994). It has thus not been possible as yet either to confirm interest in neurotrophic factors for the treatment of ALS, or to exploit their properties for a possible therapeutic approach.

On account of this, at the present time there is no

means allowing ALS to be cured and very few medicaments having a therapeutic effect. Rilutek™ is the only treatment available today. The administration of riluzole (Rilutek²) allows the progression of the disease to be slowed, but no

5 therapeutic effect has been demonstrated on the motor function. In addition, clinical trials based on the administration of CNTF have been interrupted prematurely for lack of results (Barinaga et al., 1994). Thus today there exists a real and important need to have available a method

10 allowing motor neurone disorders to be treated, and in particular ALS.

The object of the present invention is to propose a novel approach for the treatment of the pathologies of motor neurones, such as ALS, based on gene therapy. More

15 particularly, the present invention describes vector systems allowing the survival of motor neurones involved in these pathologies to be promoted directly, by the efficient and prolonged expression of certain trophic factors.

A first aspect of the invention relates to a method of

20 treatment of ALS comprising the systemic administration of a nucleic acid coding for a neurotrophic factor. Another aspect of the invention relates to the use of a nucleic acid coding for a neurotrophic factor for the preparation of a pharmaceutical composition intended for the treatment of

25 ALS. Another aspect of the invention resides in the construction of particular vectors allowing the expression of therapeutically effective quantities, in relation to ALS,

of trophic factors. Another aspect of the invention relates to the administration of expression systems allowing the production of one or more trophic factors, as well as pharmaceutical compositions comprising the said expression

5   systems. It likewise relates to the creation of novel vectors allowing the co-expression of trophic factors *in vivo*.

The present invention thus more precisely relates to a novel method of treatment of ALS based on the continuous *in*

10   *vivo* expression of trophic factors.

The present invention now shows that it is possible *in vivo* to obtain a particularly pronounced therapeutic effect by *in vivo* production of neurotrophic factors. The applicant has especially shown that the *in vivo* injection of

15   neurotrophic factor expression systems, by the systemic route, allows a continuous production of therapeutic factors to be obtained, and that this production was sufficient to obtain a therapeutic benefit in the motor neurone pathologies, in particular ALS. Thus, the applicant has

20   shown that the systemic administration of these expression systems leads to a very significant increase in the duration of life, accompanied by an improvement in the motor response evoked, as determined by electromyography. The results described demonstrate that this administration route allows

25   an appropriate bioavailability of neurotrophic factors to be obtained, without toxicity effects. This therapeutic approach thus allows therapeutically active quantities of

molecules to be produced, while remaining below the
threshold of toxicity of these molecules. Thus, even though
a protein of the size of a neurotrophic factor, administered
in a systemic manner, only penetrates the nervous system
5 with a low efficacy because of the blood-brain barrier, the
method of the invention unexpectedly allows a significant
therapeutic effect to be obtained. In addition, the method
of the invention allows doses of therapeutic factors to be
used which are below the toxicity threshold and do not
10 induce secondary effects.

A first object of the invention thus resides in a
method of treatment of ALS comprising the administration, by
the systemic route, of an expression system of a
neurotrophic factor. Thus the present invention provides the
15 use of a neurotrophic factor system for the preparation of a
pharmaceutical composition for the treatment of ALS, by
systemic administration. The invention likewise relates to a
method to prolong the duration of life of mammals suffering
from ALS, comprising the administration by the systemic
20 route of an expression system of a neurotrophic factor.

In the sense of the invention, the term "expression
system" designates any construct allowing the *in vivo*
expression of a nucleic acid coding for a neurotrophic
factor. Preferably, the expression system comprises a
25 nucleic acid coding for a neurotrophic factor operably
linked to a transcriptional control element (expression
cassette). The term "operably linked" refers to a

juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is litigated in such a way that expression of the

5 coding sequence is acheived under condition compatible with the control sequences. The nucleic acid can be a DNA or an RNA. Concerning a DNA, it is possible to use a cDNA, a genomic DNA (gDNA) or a hybrid DNA, that is to say a DNA containing one or more introns of the genomic DNA, but not

10 all. The DNA can likewise be a synthetic or semi-synthetic DNA, and in particular a DNA synthesized artificially to optimize the codons or create truncated forms.

The transcriptional control element can comprise any promoter functional in a mammalian cell, preferably human.

15 It can be the promoter region naturally responsible for the expression of the neurotrophic factor considered when this is capable of functioning in the cell or organism concerned. It can likewise be regions of different origin (responsible for the expression of other proteins, or even synthetic).

20 Preferably, it can be promoter regions of eucaryotic or viral genes. For example, it can be promoter regions from the genome of the target cell. Among the eucaryotic promoters, it is possible to use any promoter or derived sequence stimulating or suppressing the transcription of a

25 gene in a manner which is specific or non-specific, inducible or non-inducible, strong or weak. It can in particular be ubiquitous promoters (promoter of, for

example, the HPRT, PGK, α-actin and tubulin genes),
promoters of the intermediate filaments (for example, the
promoter of the GFAP, desmin, vimentin, neurofilaments or
keratin genes), promoters of therapeutic genes (for example
5   the promoter of the MDR, CFTR, Factor VIII and ApoAI genes),
specific tissue promoters (promoter of the pyruvate kinase,
villin, fatty acid-bound intestinal protein, smooth muscle
or α-actin gene) or even of promoters responding to a
stimulus (for example a steroid hormone receptor or a
10   retinoic acid receptor). In the same way, it can be promoter
sequences from the genome of a virus, such as, for example,
the promoters of the E1A and adenovirus MLP genes, the early
promoter of CMV, or even the promoter of LTR of RSV. The
transcriptional control element may further comprise
15   additional sequences, for example enhancer elements, such as
activation sequences, regulation sequences or sequences
allowing tissue-specific or high-level expression.

Within the context of the invention, a constitutive
eucaryotic or viral promoter is preferably used. It is more
20   particularly a promoter chosen from among the promoter of
the HPRT, PGK, α-actin, tubulin genes or the promoter of the
E1A and adenovirus MLP genes, the early promoter of CMV, or
even the promoter of LTR of RSV.

In addition, the expression cassette preferably
25   contains a signal sequence directing the product synthesized
in to secretion pathways of the target cell. This signal
sequence can be the natural signal sequence of the product

synthesized, but it can likewise be any other functional signal sequence, or an artificial signal sequence.

Finally, the expression cassette generally comprises a region situated in 3', which specifies a transcription end

5 signal and a polyadenylation site.

The trophic factors used in the context of the invention are essentially classed under three families: the neurotrophin family, the neurokine family and the TGF beta family (for review, see Henderson, Adv. Neurol. 68 (1995)

10 235).

In the neurotrophin family, it is preferred in the context of the invention to use BDNF, NT-3 or NT-4/5.

The neurotrophic factor derived from the brain (BDNF), described by Thoenen (Trends in NeuroSci. 14 (1991) 165), is

15 a protein of 118 amino acids and of molecular weight 13.5 kD. *In vitro*, BDNF stimulates the formation of neurites and the survival in culture of ganglionic neurones of the retina, cholinergic neurones of the septum as well as dopaminergic neurones of the mesencephalon (review by

20 Lindsay in Neurotrophic Factors, Ed, (1993) 257, Academic Press). The DNA sequence coding for human BDNF and for rat BDNF has been cloned and sequenced (Maisonpierre et al., Genomics 10 (1991) 558), as well as especially the sequence coding for porcine BDNF (Leibrock et al., Nature 341 (1989)

25 149). Though its properties would be potentially interesting, the therapeutic administration of BDNF is running into various obstacles. In particular, the lack of

bioavailability of BDNF limits any therapeutic use. The brain-derived neurotrophic factor (BDNF) produced in the context of the present invention can be human BDNF or animal BDNF.

5   Neurotrophin 3 (NT3) is a secreted protein of 119 aa which allows the *in vitro* survival of neurones even at very low concentrations (Henderson et al., Nature 363, 266-270 (1993)). The sequence of the cDNA coding for human NT3 has been described (Hohn et al., Nature 344 (1990) 339).

10   The TGF-B family especially comprises the glial cell-derived neurotrophic factor. The glial cell-derived neurotrophic factor, GDNF (L.-F. Lin et al., Science, 260, 1130-1132 (1993)) is a protein of 134 amino acids and of molecular weight 16 kD. It has the essential capacity *in*

15 *vitro* of promoting the survival of dopamineric neurones and of motor neurones (review in Henderson, 1995). The glial cell-derived neurotrophic factor (GDNF) produced in the context of the present invention can be human GDNF or animal GDNF. The cDNA sequences coding for human GDNF or rat GDNF

20 have been cloned and sequenced (L.-F. Lin, D. Doherty, J. Lile, S. Besktesh, F. Collins, Science, 260, 1130-1132 (1993)).

       Another neurotrophic factor which can be used in the context of the present invention is CNTF ("Ciliary

25 NeuroTrophic Factor"). CNTF is a neurokine capable of preventing the death of neurones. As indicated above, clinical trials have been interrupted prematurely for lack

of results. The invention now allows the prolonged and continuous *in vivo* production of CNTF, on its own or in combination with other trophic factors, for the treatment of ALS. cDNA and the human and murine CNTF gene have been

5 cloned and sequenced (EP385 060; WO91/04316).

Other neurotrophic factors which can be used in the context of the present invention are, for example, IGF-1 (Lewis et al., 1993) and fibroblast growth factors (FGFa, FGFb). In particular, IGF-1 and FGFa are very interesting

10 candidates. The sequence of the gene of FGFa has been described in the literature, as well as vectors allowing its expression *in vivo* (WO95/25803).

The genes coding for BDNF, GDNF, CNTF and NT3 are all particularly interesting for the implementation of the

15 present invention.

According to a first embodiment, the expression system of the invention allows the production of a single neurotrophic factor *in vivo*. In this case, the expression system only contains an expression cassette. Preferably, the

20 expression system of the invention allows the *in vivo* production of a neurotrophic factor chosen from among neurotrophins, neurokines and TGFs. It is more preferably a factor chosen from among BDNF, GDNF, CNTF, NT3, FGFa and IGF-1.

25 According to another embodiment, the expression system of the invention allows the production of two neurotrophic factors *in vivo*. In this embodiment, the expression system

contains either two expression cassettes or a single
cassette allowing the simultaneous expression of two nucleic
acids (bicistronic unit). When the system comprises two
expression cassettes, these can use identical or different

5   transcriptional control elements. Further, it will be
appreciated that more than two neurotrophic factors may be
produced *in vivo*. This can be achieved using several
expression cassettes. Again, the expression cassettes may
comprise identical or different transcriptional control

10   elements.

Preferably, the expression system of the invention
allows the *in vivo* production of combinations of the
following neurotrophic factors: BDNF and GDNF; BDNF and NT3;
GDNF and NT3, CNTF and BDNF, CNTF and NT3, CNTF and GDNF.

15   The Applicant has in fact shown that the administration
of 2 neurotrophic factor expression systems is manifested by
a significant therapeutic effect. In the expression systems
of 2 neurotrophic factors, transcriptional control elements
of identical or similar strength are used, and an identical

20   or similar number of copies of nucleic acids. Generally, the
respective quantity of the two factors produced *in vivo* is
sufficiently close. However, it may be preferable in certain
situations to produce different quantities of each factor.
In this case, it is possible to use either transcriptional

25   control elements of different strength, or a system in which
numbers of copies of different genes are present, or to vary
the doses administered.

a viral vector derived from the adenoviruses. Adenoviruses
are linear double-stranded DNA viruses of a size of
approximately 36 kb (kilobases). Their genome comprises a
repeated inverted sequence (ITR) at each end, an

5   encapsidation sequence (Psi), early genes and late genes.
The principal early genes are contained in the E1, E2, E3
and E4 regions. Among these, the genes contained in the E1
region especially are necessary for viral propagation. The
principal late genes are contained in the L1 to L5 regions.

10 The genome of the Ad5 adenovirus has been entirely sequenced
and is accessible in databases (see especially Genebank
M73260). In the same way, parts, or even the whole of other
adenoviral genomes (Ad2, Ad7, Ad12, etc.) have likewise been
sequenced.

15   For their use as gene-transfer vectors, various
constructs derived from adenoviruses have been prepared,
incorporating various therapeutic genes. More particularly,
the constructs described in the prior art are adenoviruses
from which the E1 region has been deleted and which are

20 essential for viral replication, at the level of which are
inserted heterologous DNA sequences (Levrero et al., Gene
101 (1991) 195; Gosh-Choudhury et al., Gene 50 (1986) 161).
Moreover, to improve the properties of the vector, it has
been proposed to create other deletions or modifications in

25 the genome of the adenovirus. Thus, a heat-sensitive point
mutation has been introduced into the mutant ts125, allowing
the 72kDa DNA linkage protein (DBP) to be inactivated (Van

der Vliet et al., 1975). Other vectors comprise a deletion of another region essential to viral replication and/or propagation, the E4 region. The E4 region is in fact involved in the regulation of the expression of late genes,

5   in the stability of late nuclear RNA, in the suppression of the expression of proteins of the host cell and in the efficacy of the replication of viral DNA. Adenoviral vectors in which the E1 and E4 regions are deleted thus have a transcription background noise and a very reduced expression

10   of viral genes. Such vectors have been described, for example, in the Applications WO94/28152, WO95/02697, WO96/22378. In addition, vectors carrying a modification at the level of the IVa2 gene have likewise been described (WO96/10088).

15   The recombinant adenoviruses described in the literature are produced starting from various adenovirus serotypes. In fact, various adenovirus serotypes exist whose structure and properties vary somewhat, but which have a comparable genetic organization. More particularly, the

20   recombinant adenoviruses can be of human or animal origin. Concerning the adenoviruses of human origin, it is preferentially possible to mention those classes in group C, in particular the adenoviruses of type 2 (Ad2), 5 (Ad5), 7 (Ad7) or 12 (Ad12). Among the different adenoviruses of

25   animal origin, the adenoviruses of canine origin may be mentioned, and especially all the strains of the CAV2 adenoviruses [Manhattan or A26/61 (ATCC VR-800) strain, for

example]. Other adenoviruses of animal origin are especially mentioned in the Application WO94/26914 incorporated by reference in the present application.

In a preferred mode of implementation of the invention, the recombinant adenovirus is a human adenovirus of group C. More preferably, it is an Ad2 or Ad5 adenovirus.

The recombinant adenoviruses are produced in an encapsidation line, that is a line of cells capable of trans-complementing one or more of the deficient functions in the recombinant adenoviral genome. One of these lines is, for example, the 293 line into which a part of the genome of the adenovirus has been integrated. More precisely, the 293 line is a line of renal human embryonic cells containing the left end (approximately 11-12%) of the genome of the serotype 5 adenovirus (Ad5), comprising the left ITR, the encapsidation region, the E1 region, including E1a and E1b, the region coding for the pIX protein and a part of the region coding for the pIVa2 protein. This line is capable of trans-complementing defective recombinant adenoviruses for the E1 region, that is devoid of any or part of the E1 region, and of producing viral stocks having very high titres. This line is likewise capable of producing, at a permissive temperature (32EC), stocks of virus containing in addition the heat-sensitive E2 mutation. Other cell lines capable of complementing the E1 region have been described, based especially on A549 human lung carcinoma cells (WO94/28152) or on human retinoblasts (Hum. Gen. Ther.

(1996) 215). Moreover, lines capable of trans-complementing several functions of the adenovirus have likewise been described. In particular, it is possible to mention lines complementing the E1 and E4 regions (Yeh et al., J. Virol.

5   70 (1996) 559; Cancer Gen. Ther. 2 (1995) 322; Krougliak et al., Hum. Gen. Ther. 6 (1995) 1575) and lines complementing the E1 and E2 regions (WO94/28152, WO95/02697, WO95/27071). The recombinant adenoviruses are usually produced by introduction of the viral DNA into the encapsidation line,

10   followed by lysis of the cells after approximately 2 or 3 days (the kinetics of the adenoviral cycle being from 24 to 36 hours). After the lysis of the cells, the recombinant viral particles are isolated by centrifugation in a caesium chloride gradient. Alternative methods have been described

15   in the Application FR96 08164.

The expression cassette of the therapeutic gene(s) can be inserted into various sites of the genome of the recombinant adenovirus according to the techniques described in the prior art. It can first of all be inserted at the

20   level of the E1 deletion. It can likewise be inserted at the level of the E3 region, in addition or in substitution of sequences. It can likewise be localized at the level of the deleted E4 region. For the construction of vectors carrying two expression cassettes, one can be inserted at the level

25   of the E1 region, the other at the level of the E3 or E4 region. The two cassettes can likewise be introduced at the level of the same region.

As indicated above, in the case of expression systems containing several expression cassettes, the cassettes can be carried by separate vectors, or by the same vector. The present invention is more specifically aimed at the

5   perfecting of vectors which are particularly efficacious at delivering *in vivo* and in a localized manner therapeutically active quantities of GDNF, of BDNF, of NT3 and of CNTF. More precisely, the present invention relates to the systemic injection of an expression system comprising two gene-

10   transfer vectors each carrying a gene coding for a neurotrophic factor. The invention likewise relates to the systemic injection of an expression system comprising a bicistronic vector allowing the coexpression of the two genes. Preferably, the present invention relates to the

15   systemic injection of an expression system comprising two vectors, one carrying the gene coding for CNTF and the other the gene coding for NT3, or one the gene coding for CNTF and the other the gene coding for BDNF, or one the gene coding for GDNF and the other the gene coding for NT3.

20   More preferably, the transfer vectors used are adenoviral vectors. The Applicant has in fact shown the efficacy of the use of adenovirus coding for neurotrophic factors injected by the i.v. route in the treatment of an animal model of ALS. In particular, the results presented in

25   the examples show, for the first time in an animal model of ALS, a significant increase in the duration of life, accompanied by better electromyographic performances. The

only treatment today proposed for patients suffering from ALS is riluzole (Rilutek) which increases by several months the hope of survival of the sufferers. It has likewise been demonstrated that riluzole administered to $FALS_{G93A}$ mice is

5 able to increase by 13 days their average life span (Gurney et al., 1996). It can thus be predicted that any treatment increasing by more than 13 days the life span of $FALS_{G93A}$ mice is capable of providing to the patients a therapeutic benefit which is superior to that of riluzole. The results

10 presented in the examples show that the therapeutic approach according to the invention allows the average life span of $FALS_{G93A}$ mice to be increased by approximately 30 days. This constitutes a very significant improvement in the life span, and represents the first demonstration of a therapeutic

15 benefit of this importance on models of ALS.

According to the invention, the production *in vivo* of trophic factors is obtained by systemic administration. The results presented in the examples show that this mode of administration allows a regular and continuous production of

20 a trophic factor by the body of the patient himself to be obtained, and that this production is sufficient to generate a significant therapeutic effect. Systemic administration is preferably an intravenous or intra-arterial injection. Intravenous injection is particularly preferred. This mode

25 of injection is likewise advantageous in terms of tolerance and of ease of access. It additionally allows greater volumes to be injected than intramuscular injection, and in

a repeated manner.

The present invention further provides a pharmaceutical composition for the treatment of degenerative diseases of motor neurones comprising a system allowing the expression of two neurotrophic factors together with a pharmaceutically acceptable carrier or diluent. The pharmaceutical compositions of the invention preferably contain pharmaceutically acceptable vehicles for an injectable formulation. In particular, they can be sterile, isotonic saline solutions (for example, monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride, or mixtures of such salts), or dry compositions, especially lyophilized compositions, which, by addition, as the case may be, of sterilized water or physiological serum, allow the formation of injectable solutions. Other excipients can be used, such as, for example, stabilizer proteins (especially human serum albumin: FR96 03074) or a hydrogel. This hydrogel can be prepared starting from any biocompatible and non-cytotoxic polymer (homo or hetero). Such polymers have been described, for example, in the Application WO93/08845. Some of these, such as especially those obtained starting from ethylene oxide and/or propylene oxide are commercially available. In addition, when the expression system is composed of plasmid vectors, it is preferred to add to the pharmaceutical compositions of the invention chemical or biochemical agents favouring the transfer of genes. In this respect, it is possible more

particularly to mention cationic polymers of the polylysine type, (LKLK)n, (LKKL)n such as described in the Application WO95/21931, polyethylene imine (WO96/02655) and DEAE-dextran or even cationic or lipofectant lipids. They have the

5   property of condensing DNA and of promoting its association with the cell membrane. Among the latter, it is possible to mention lipopolyamines (lipofectamine, transfectam, such as described in the Application WO95/18863 or WO96/17823) various cationic or neutral lipids (DOTMA, DOGS, DOPE, etc.)

10   as well as peptides of nuclear origin (WO96/25508), possibly functionalized to target certain tissues. The preparation of a composition according to the invention using such a chemical vector is carried out according to any technique known to the person skilled in the art, generally by simple

15   contacting of the different components.

The doses of expression system administered depend on several factors, and especially on the vector used, on the neurotrophic factor(s) involved, on the type of promoter used, on the stage of the pathology or even on the duration

20   of the treatment studied. Generally, the expression system is administered in the form of doses comprising from 0.1 to 500 mg of DNA per kg, preferably from 1 to 100 mg of DNA per kg. Doses of 10 mg of DNA/kg approximately are generally used.

25   Being recombinant adenoviruses, they are preferably formulated and administered in the form of doses of between 10^4 and 10^{14} pfu, and preferably 10^6 to 10^{10} pfu. The term pfu

("plaque forming unit") corresponds to the infectious power of an adenovirus solution, and is determined by infection of an appropriate cell culture, and is a measure, generally after 15 days, of the number of infected cell plaques. The

5   techniques of determination of the pfu titre of a viral solution are well documented in the literature.

Injection can be carried out by means of various devices, and in particular by means of syringes or by perfusion. Injection by means of syringes is preferred. In

10   addition, repeated injections can be performed to increase still further the therapeutic effect.

According to a variant of the invention, this treatment can likewise be applied in combination with riluzole. The present invention thus further provides a pharmaceutical

15   composition comprising an expression system according to the invention and a pharmacologically effective quantity of riluzole together with a pharmaceutically acceptable carrier or diluent for simultaneous administration or administration at intervals of time.

20   The results presented below illustrate the present invention without otherwise limiting its context. They demonstrate the particularly advantageous properties of the method of the invention which constitutes, to our knowledge, the first demonstration on an animal model of such a

25   therapeutic benefit for ALS.

KEY TO FIGURES

Figure 1: Comparison of the electromyographic performances of ALS mice with or without administration of a CNTF-GDNF combination expression system.

Figure 2: Comparison of the electromyographic performances
5 of ALS mice with or without administration of an NT3 expression system.

EXAMPLES

1.   Material and methods

10 All of the experiments described below (construction of adenovirus, injection into mice, functional measurements) were carried out in an L3 confinement laboratory.

1 - Animals

Several lines of transgenic mice expressing mutated
15 forms of SOD responsible for the familial forms of ALS have been constructed to attempt to obtain a murine model of the pathology. Transgenic mice overexpressing mutated human SOD carrying a substitution of glycine 93 by alanine ($FALS_{G93A}$ mice) have a progressive motor neurone degeneration
20 expressing itself by a paralysis of the limbs, and die at the age of 4 - 6 months (Gurney et al., 1994). The first clinical signs consist of a trembling of the limbs at approximately 90 days, then a reduction in the length of the step at 125 days (Chiu et al., 1995). At the histological
25 level, vacuoles of mitochondrial origin can be observed in the motor neurones from approximately 37 days, and a motor neurone loss can be observed from 90 days (Chiu et al.,

1995). Attacks on the myelinated axons are observed principally in the ventral marrow and a little in the dorsal region. Compensatory collateral reinnervation phenomena are observed at the level of the motor plaques (Chiu et al.,

5   1995).

In the examples, we have chosen to use $FALS_{G93A}$ mice. Other animal models presenting motor neurone degeneration exist (Sillevis-Smitt & De Jong, 1989, Price et al., 1994), either following an acute neurotoxic lesion

10   (treatment with IDPN, from the excitotoxins) or due to a genetic fault (wobbler, pmn, Mnd mice, HCSMA dog). Nevertheless, $FALS_{G93A}$ mice today constitute the best animal model available for the study of the physiopathological mechanisms of ALS as well as for the development of

15   therapeutic strategies. They in fact share with the familial forms of ALS a common physiopathological origin (SOD mutation), and a large number of histopathological and electromyographic characteristics.

Thus, we have characterized in the laboratory the

20   electromyographic performances of the $FALS_{G93A}$ mice and shown that the $FALS_{G93A}$ mice fulfil the criteria of Lambert for ALS (Kennel et al., 1996): (1) reduction in the number of motor units with a concomitant collateral reinnervation; (2) presence of spontaneous denervation activity (fibrillations)

25   and of fasciculation in the hind and fore limbs; (3) modification of the speed of motor conduction correlated with a reduction in the motor response evoked; (4) no

sensory attack. Moreover we have shown that the facial nerve attacks were rare, even in the aged FALS$_{G93A}$ mice, which is also the case in the patients.

The FALS$_{G93A}$ mice come from Transgenic Alliance
5 (L'Arbresle, France). Pregnant females are delivered to us each week. They give birth in the laboratory animal house. The immature mouse heterozygotes developing the disease are identified by PCR after taking a piece of tail and DNA extraction.

10

2.   Expression systems

2.1. Plasmid vectors

Various plasmid vectors allowing the expression of one or two neurotrophic factors can be used. It is possible to
15 mention, for example, the pCRII-BDNF and pSh-Ad-BDNF plasmids, which contain an expression and BDNF secretion cassette (WO95/25804). It is likewise possible to mention the p-LTR-IX-GDNF plasmids containing a nucleic acid coding for GDNF under the control of the promoter LTR (WO95/26408).
20 It is understood that any plasmid containing a replication origin and a marker gene can be used to construct an expression system according to the invention by insertion of one or more expression cassettes of a neurotrophic factor. The plasmids can be prepared in a eucaryotic or procaryotic
25 cell host.

2.2.- Adenovirus

As indicated above, the viral vectors, and especially
the adenoviruses, constitute a particularly preferred
embodiment of the invention.

The recombinant adenoviruses used below were obtained
by homologous recombination according to the techniques
described and well known in the prior art. In brief, they
are constructed in 293 cells by recombination between a
fragment of linearized viral genome (d1324) and a plasmid
containing the left ITR, the encapsidation sequences, the
transgene as well as its promoter and viral sequences
allowing recombination. The viruses are amplified in 293
cells. They are regularly repurified in the P3 in our
laboratory. The viral genomes can likewise be prepared in a
procaryotic cell according to the technique described in the
Application WO96/25506. The following viruses were more
particularly used:

- Ad-CNTF: Recombinant adenovirus of Ad5 serotype
comprising, inserted in its genome in place of the deleted
E1 region, an expression cassette of the CNTF compound of
the cDNA coding for CNTF under the control of a
transcriptional promoter (in particular the LTR of RSV). The
details of the construct are given in the Application
WO94/08026. An alternative construct comprises a
supplementary deletion in the E4 region, such as described
in the Application WO96/22378.

- AD-GDNF: Recombinant adenovirus of Ad5 serotype
comprising, inserted in its genome in place of the deleted

E1 region, an expression cassette of the GDNF compound of the cDNA coding for GDNF under the control of a transcriptional promoter (in particular the LTR of RSV). The details of the construct are given in the Application

5   WO95/26408). An alternative construct comprises a supplementary deletion in the E4 region, such as described in the Application WO96/22378.

- Ad-NT3: Recombinant adenovirus of Ad5 serotype comprising, inserted in its genome in place of the deleted

10 E1 region, an expression cassette of the NT3 compound of the cDNA coding for NT3 under the control of a transcriptional promoter (in particular the LTR of RSV). An alternative construct comprises a supplementary deletion in the E4 region, such as described in the Application WO96/22378.

15   - Ad-BDNF: Recombinant adenovirus of Ad5 serotype comprising, inserted in its genome in place of the deleted E1 region, an expression cassette of the BDNF compound of the cDNA coding for BDNF under the control of a transcriptional promoter (in particular the LTR of RSV). The

20 details of the construct are given in the Application WO95/25804. An alternative construct comprises a supplementary deletion in the E4 region, such as described in the Application WO96/22378.

- Ad-FGFa: Recombinant adenovirus of Ad5 serotype

25 comprising, inserted in its genome in place of the deleted E1 region, an expression cassette of the FGFa compound of the cDNA coding for FGFa under the control of a

transcriptional promoter (in particular the LTR of RSV). The details of the construct are given in the Application WO95/25803. An alternative construct comprises a supplementary deletion in the E4 region, such as described
5   in the Application WO96/22378.

The functionality of the viruses constructed is verified by infection of fibroblasts in culture. The presence of the corresponding neurotrophic factor is analysed in the culture supernatant by ELISA and/or by
10   demonstrating the trophic properties of this supernatant on neuronal primary cultures.

3. - Administration of recombinant adenovirus

The adenoviruses coding for the neurotrophic factors
15   are administered by the intravenous route (caudal vein) with the aid of a Hamilton7-type microsyringe. 10^9 pfu of each of the adenoviruses are thus injected in a final volume of 200 ml.

4. - Electromyography
20

While their physical state allows it, the animals are anaesthetized by intraperitoneal injection of a mixture of diazepam (Valium7, Roche, France) and of ketamine hydrochloride (Kétalar7, Parke-Davis, France) at a rate of 2
25   mg/g and 60 mg/g of body weight respectively.

The electromyograph used is a latest generation apparatus (Keypoint7) having all of the software necessary

for the acquisition and for the processing of electromyographic signals. This material is leased to Dantec (Les Ulis, France).

Electromyography of stimulo-detection: motor response evoked (REM)

When an electric shock is applied to a nerve, the muscles innervated by this nerve are the site of an electrical response. This survives for a certain time (distal latency) which corresponds to the conduction time of the stimulation as far as the synapses, to which is added the transmission time of the signal in the synapse. The amplitude of the response is proportional to the quantity of innervated muscular fibres.

For purely practical reasons, we have chosen to stimulate the sciatic nerve picking up the motor response evoked at the level of the gastrocnemius muscle of the calf. Five needle electrodes (Dantec) are directly implanted and connected to the electromyograph according to the following scheme: (a) 2 stimulation electrodes are placed, one (active electrode) on the path of the sciatic nerve, the other (reference electrode) at the base of the tail; (b) 2 detection electrodes are implanted, one in the gastrocnemius muscle (active electrode), the other on the corresponding tendon (reference electrode); (c) finally one electrode is connected to earth and is implanted between the two active electrodes, in the thigh of the animal. The amplitude and the latency of the REM of the muscle are measured with a

stimulation of its motor nerve. This lasts 200 ms at a supramaximal intensity which corresponds to 150% of the intensity allowing the maximum action potential to be obtained. In the adult mouse, if the muscle and the nerve studied are sound, and under the conditions described above, the amplitude of the response evoked is more than or equal to 80 mV, and the latency time is in general equal to 0.6 ms.

5.   Administration of an expression system producing a CNTF-GDNF combination

10^9 pfu of each of the Ad-CNTF and Ad-GDNF adenoviruses were injected (caudal vein) with the aid of a microsyringe in a final volume of 200 ml into 4 animals aged 99 days. In the course of time, the electromyographic performances of the animals were followed and compared with a control group. The average duration of life was likewise recorded.

Electromyography

The results obtained are presented in Figure 1. A lowering of the amplitude of the motor response evoked (REM) is observed in the gastrocnemius of the treated $FALS_{G93A}$ mice (AdCNTF+AdGDNF) as well as non-treated $FALS_{G93A}$ mice. This lowering reflects the progressive denervation process which is a characteristic of ALS. Nevertheless, the treated mice show an REM amplitude which is systematically higher than that of the controls, demonstrating a slowing of the functional attack following treatment.

Longevity

The life span of the animals is indicated in the tables below.

Treated animals

Animal No.	Age at death
1779-5	188
1779-6	170
1779-7	176
1779-8	155
Average	172.2
SEM	6.86

5

Non-treated animals

Animal No.	Age at death
35-5	142
35-8	135
35-9	151
35-50	125
35-60	147
35-90	155
Average	142.5
SEM	4.51

The results show that all the animals of the treated

group are dead at an age which is higher than or equal to the age of the oldest living animal in the control group. These results likewise show an increase in the life span in the treated animals of 30 days on average, with respect to

5   the control animals. These results are particularly unexpected and, compared to 13 days obtained with Rilutek[R], demonstrate the therapeutic potential of the method of the invention.

10   **6.   Administration of an expression system producing NT3**

10^9 pfu of Ad-NT3 adenovirus were injected (caudal vein) with the aid of a microsyringe in a final volume of 200 ml into 4 animals aged 99 days. In the course of time, the electromyographic performances of the animals are

15   followed and compared to a control group. The results obtained are presented in Figure 2 and show that the treated animals show an REM amplitude higher than that of the controls, demonstrating a slowing of the functional attack following treatment.

20

7.   Administration of an expression system producing a CNTF-NT3 combination

10^9 pfu of each of the Ad-CNTF and Ad-NT3 adenoviruses were injected (caudal vein) with the aid of a microsyringe

25   in a final volume of 200 ml into 4 animals aged 99 days. In the course of time, the electromyographic performances of the animals were followed and compared with a control group.

The average life span is likewise recorded.

8.   Administration of an expression system producing a BDNF-NT3 combination

5   10^9 pfu of each of the Ad-BDNF and Ad-NT3 adenoviruses were injected (caudal vein) with the aid of a microsyringe in a final volume of 200 ml into 4 animals aged 99 days. In the course of time, the electromyographic performances of the animals were followed and compared with a control group.

10   The average life span is likewise recorded.

9.   Administration of an expression system producing BDNF

10^9 pfu of Ad-BDNF adenovirus were injected (caudal vein) with the aid of a microsyringe in a final volume of

15   200 ml into 4 animals aged 99 days. In the course of time, the electromyographic performances of the animals are followed and compared with a control group. The average life span is likewise recorded.

20   References

-AKLI S. et al. Nature genet., 3,224-228,1993

-APPEL S.H. et al. Autoimmunity as an etiological factor in sporadic amyotrophic lateral sclerosis. In Serratrice G.T. and Munsat T.L. eds. Pathogenesis and therapy of amyotrophic

25   lateral sclerosis. Advances in Neurology, 68, pp. 47-58, 1995.

Lippincott-Raven publishers, Philadelphia.

-BAJOCCHI G. et al. Nature genet., 3,229-234, 1993.

-BARKATS M. et al. Neuroreport, 7,497-501, 1996.

-BARINAGA M. Science 264, 772-774 1994.

-CASTEL BARTHE M.N. et al. Neurobiology of Disease, 3, 76-

5   86, 1996.

-CHIU A.Y., et al. Mol. Cell. Neurosci., 6, 349-362, 1995.

-DAVIDSON B.L., et al. Nature genet., 3, 219-223, 1993.

-DITTRICH F. Ann. Neurol., 35, 151-163, 1994.

-FINIELS F. et al. Neuroreport, 7,373-378, 1995.

10   -GASTAUT J.L. The viral hypothesis. In Serratrice G.T. and

Munsat T.L. eds. Pathogenesis and therapy of amyotrophic

lateral sclerosis. Advances in Neurology, 68, pp. 135-138,

1995. Lippincott-Raven publishers, Philadelphia.

-GURNEY M.E., PU H., CHIU A.Y. et al. Science, 264, 1772-

15   1775, 1994.

-GURNEY M.E., CUTTING F.B., ZHAI P. et al. Ann. Neurol., 39,

147-157, 1996.

-HENDERSON C.E., CAMU W., METTLING C. et al. Nature, 363,

266-270, 1993.

20   -HENDERSON C.E. et al. Science, 266, 1062-1064, 1994.

-HENDERSON C.E. Neurotrophic factors as therapeutic agents

in amyotrophic lateral sclerosis: potential and pitfalls. In

Serratrice G.T. and Munsat T.L. eds.

Pathogenesis and therapy of amyotrophic lateral sclerosis.

25   Advances in Neurology, 68, pp. 235-240, 1995. Lippincott-

Raven publishers, Philadelphia.

-HORELLOU P., VIGNE E., CASTEL M.N. et al. Neuroreport, 6,

-HORELLOU P., VIGNE E., CASTEL M.N. et al. Neuroreport, 6, 49-53, 1994.

-HUGHES R.A. et al. Neuron, 10, 369-377, 1993.

-KENNEL P.F., FINIELS F., REVAH F. et al. Neuroreport, 7,

5   1427-1431, 1996a.

-KENNEL P.F. et al. Neurobiology of Disease, in press, 1996b.

-Le GAL La SALLE G. et al. Science, 262, 430-433, 1993.

-LEWIS M.E. et al. Exp. Neurol., 124, 73-88, 1993.

10   -OPPENHEIM R.W., YIN Q.W., PREVETTE D. et al. Nature, 360, 755-757, 1992.

-OPPENHEIM R.W. et al. Nature, 373, 344-346, 1995.

-PENNICA D., ARCE V., SWANSON T.A. et al. Neuron, 17, 63-74, 1996.

15   -PRICE D.L. et al. Neurobiol. Disease, 1, 3-11, 1994.

-ROSEN D.R., SIDDIQUE T., PATTERSON D. et al. Nature, 362, 59-62, 1993.

-ROTHSTEIN J.D. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. In Serratrice G.T. and

20   Munsat T.L. eds. Pathogenesis and therapy of amyotrophic lateral sclerosis. Advances in Neurology, 68, pp. 7-20, 1995. Lippincott Raven publishers, Philadelphia.

-ROWLAND L.P. Proc. Natl. Aca. Sci. USA, 92, 1251-1253, 1995.

25   -RUBIN B.A. and RORKE L.B. Adenovirus vaccines. In Plotkin and Mortimer eds, Vaccines, pp. 492-512, 1988. W.B. Saunders, Philadelphia.

-SENDTNER M. et al. Nature, 358, 502-504, 1992a.

-SENDTNER M., HOLTMANN B., KOLBECK R. Nature, 360, 757-759, 1992b.

-SILLEVIS SMITT P.A.E. et al. J. Neurol. Sci., 91, 231-258, 1989.

-VEJSADA R., SAGOT Y. and KATO A.C. Eur. J. Neurosci., 7, 108-115, 1995.

-WINDEBANK A.J. Use of growth factors in the treatment of motor neuron diseases. In Serratrice G.T. and Munsat T.L. eds. Pathogenesis and therapy of amyotrophic lateral sclerosis. Advances in Neurology, 68, pp. 229-234, 1995. Lippincott-Raven publishers, Philadelphia.

-YAN Q., ELLIOTT J. and SNIDER W.D. Nature, 360, 753-755, 1992.

-YANG Y., ERTL H.C.J., and WILSON J.M. Immunity, 1, 433-442, 1994.

-YANQ., MATHESON C., LOPEX O.T. et al. J. Neurosci., 14, 5281-5291, 1994.

-YASE Y. Metal metabolism in motor neuron disease. In Chen K.M. and Yase Y. eds. Amyotrophic lateral sclerosis in Asia and Oceania, Taipei, pp. 337-356, 1984. Taiwan: National Taiwan University Press.

-YEH P., DEDIEU J.F., ORSINI C. et al. J. Virol., 70, 559-565, 1996.

-YIM M.B., et al. Proc. Natl. Acad. Sci. USA, 93, 5709-5714, 1996.

CLAIMS

1. Use of a neurotrophic factor expression system for the preparation of a pharmaceutical composition for the treatment of Amyotrophic Lateral Sclerosis (ALS) by systemic administration.

2. Use according to claim 1, characterized in that the expression system comprises an expression cassette composed of a nucleic acid coding for a neurotrophic factor operably linked to a transcriptional control element.

3. Use according to claim 1, characterized in that the expression system comprises two expression cassettes each composed of a nucleic acid each coding for a different neurotrophic factor, under the control of a transcriptional control element.

4. Use according to claim 1, characterized in that the expression system comprises an expression cassette composed of two nucleic acids coding for a different neurotrophic factor, under the control of a single transcriptional control element (bicistronic unit).

5. Use according to claim 2, characterized in that the neurotrophic factor is chosen from GDNF, CNTF, BDNF and NT3.

6. Use according to claim 3 or 4, characterized in that each nucleic acid codes for a different neurotrophic factor chosen from among GDNF, CNTF, BDNF and NT3.

7. Use according to claim 6, characterized in that the expression system comprises a nucleic acid coding for

CNTF and a nucleic acid coding for GDNF.

8. Use according to any one of claims 2 to 4, characterized in that the expression cassettes are part of a vector.

9. Use according to claim 8, characterized in that the expression cassettes are part of a plasmid vector.

10. Use according to claim 8, characterized in that the expression cassettes are part of a viral vector.

11. Use according to claim 10, characterized in that the viral vector is an adenoviral vector.

12. Use according to any one of the preceding claims, characterized in that the transcriptional control element comprises a constitutive eucaryotic or viral promoter.

13. Use according to any one of the preceding claims, characterized in that the systemic administration is an intravenous administration.

14. A pharmaceutical composition for the treatment of degenerative diseases of the motor neurones comprising a system allowing the expression of two neurotrophic factors together with a pharmaceutically acceptable carrier or diluent.

15. A composition according to claim 14, characterized in that the said system comprises two gene-transfer vectors each comprising a nucleic acid coding for a different neurotrophic factor.

16. A composition according to claim 14, characterized in that the said system comprises a gene-transfer vector

comprising a cassette allowing the concomitant expression of two different neurotrophic factors.

17. A composition according to claim 15 or 16, characterized in that the vectors are viral vectors.

18. A composition according to claim 17, characterized in that the vectors are adenoviruses.

19. A composition according to claim 15 or 16, characterized in that the vectors are plasmid vectors.

20. A composition according to claim 14, characterized in that the neurotrophic factors are chosen from among GDNF, BDNF, CNTF and NT3.

21. A composition according to claim 20, characterized in that it contains two defective recombinant adenoviruses, one carrying a nucleic acid coding for CNTF and the other for GDNF.

22. A composition according to claim 20, characterized in that it contains two defective recombinant adenoviruses, one carrying a nucleic acid coding for GDNF and the other for NT3.

23. A composition according to claim 20, characterized in that it contains two defective recombinant adenoviruses, one carrying a nucleic acid coding for BDNF and the other for NT3.

24. A composition according to claim 14, characterized in that it is injected intravenously.

25. A pharmaceutical composition comprising a neurotrophic factor expression system as defined in any one

of claims 1 to 13 and riluzole together with a pharmaceutically acceptable carrier or diluent, for simultaneous administration or administration at intervals of time.

5
26. A product comprising a neurotrophic factor expression system as defined in any one of claims 1 to 13 and riluzole as a combined preparation for simultaneous separate or sequential administration in the treatment of Amyotrophic Lateral Sclerosis.

10
27. Use according to claim 1 substantially as hereinbefore described with reference to any one of the foregoing examples.

28. A pharmaceutical composition according to claim 14 substantially as hereinbefore described with reference to
15 any one of the foregoing examples.

29. A pharmaceutical composition according to claim 25 substantially as hereinbefore described with reference to any one of the foregoing examples.

ABSTRACT

METHOD OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

5   The present application relates to a novel method for the treatment of motor neurone diseases and in particular of amyotrophic lateral sclerosis. It is based more particularly on the systemic administration of neurotrophic factor expression systems.

Figure 1

Figure 2